Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company also has developed a microfabricated nanopore device for the sustained release of therapeutic agents.
The company's NLP technology produces a generation of particles which retains the strength of the Dermazone Solutions' (SDMC) technologies, but includes the ability to produce particles of 60 nanometers to 150 nanometers which are optically clear. The use of this generation of lipid-based particle delivery system provides the ability to control the size of the final particle by controlling the number of NLPs used to assemble the finished particle. This system maintains very high loading capacity of passenger molecules and uses only safe, all natural ingredients to form both the NLPs and the final delivery system.
Digilab offers a wide range of sample preparation and liquid handling tool, and a imaging and spectroscopy products for sample identification for the Life Science, Analytical Chemistry and Diagnostic markets.
Dune Sciences is an emerging technology company specializing in products and services that will facilitate the development and commercialization of nano-enabled products. The company employs several patented and patent-pending technologies to engineer interfaces for the integration of new materials and devices in medicine, bionanotechnology, energy technologies, and nanoscience.
Ensemble Therapeutics is utilizing DNA Programmed Chemistry (DPC), an innovative method for creating new chemical bonds. Ensemble integrates DPC into a nanoscale selection system that combines chemistry, biology and informatics to discover novel compounds.
The company is focused on the use of fullerene carbon nanotubes for novel therapeutic applications specifically in the area of cancer treatment. The company's extensive carbon nanotube-related, worldwide intellectual property portfolio includes discoveries by the late Nobel Prize winner Dr Rick Smalley. The use of fullerene carbon nanotubes has the goal of solving two important problems for many cancer therapeutics, that of delivering large active agents into the desired location and of protecting normal tissue from the active agent during delivery.
Fluxion develops cellular analysis tools in the pharmaceutical, biotech and research industries. The company has developed a proprietary microfluidic platform which enables precise cellular manipulation, rapid low-volume compound addition, environmental control and software-based data acquisition.
Bionanotechnology and microfluidics provide the foundations for GeneFluidics' testing platform. The use of bionanotechnology drives high signal to noise ratios (sensitivity), while the incorporation of microfluidics permits operational simplicity.
The company's targeted nanocapsule technology is designed using a flexible formulation process and can carry large or small molecules, custom target delivery to different organs, tissues and cells, and be applied several ways including topically, intravenously, or via devices or tablets.
One of the world's foremost biotechnology companies, the company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, transplant, cancer, and diagnostic testing.
The company's SonoLysis program is focused on the development of two product candidates that involve the administration of proprietary MRX-801 micro- and nanobubbles and ultrasound with or without a thrombolytic drug to break up blood clots and restore blood flow to oxygen deprived tissues.
A spin off founded to commercialize FDEC FET nano sensor technology invented at Arizona State University.The novel nano sensor technology is capable of exponential capacitive transduction for ultra high sensitivity molecular detection, coupled with exceptional selectivity.